Please try another search
For the three months ended 31 March 2022, AnyGen Co Ltd revenues increased 81% to W3.66B. Net loss increased 44% to W1.15B. Revenues reflect Clinical Use(CMO) Peptide segment increase from W717.7M to W2.1B, For Research And Development Peptide segment increase from W591.2M to W1.31B, South Korea segment increase of 92% to W3.55B. Higher net loss reflects R & D Expense increase from W275.8M to W800M (expense).
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 1284.95 | 1002.37 | 1630.39 | 1693.2 |
Gross Profit | -2386.86 | 88.12 | -472.14 | 289.48 |
Operating Income | -3408.96 | -679.65 | -1766.04 | -862.11 |
Net Income | -4658.14 | -863.72 | -2477.23 | -1080.29 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 20995 | 24705 | 25519.97 | 28645.28 |
Total Liabilities | 10475.03 | 9540.98 | 15590.06 | 16329.51 |
Total Equity | 10519.98 | 15164.02 | 9929.91 | 12315.77 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -584.97 | -876.55 | -663.65 | -1256.73 |
Cash From Investing Activities | 394.15 | 880.43 | 1912.6 | -2707.35 |
Cash From Financing Activities | 684.15 | 263.13 | -1420.68 | 3907.85 |
Net Change in Cash | 496.12 | 266.86 | -173.34 | -56.18 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review